Diabetology & Metabolic Syndrome最新文献

{"title":"Effects of SGLT2 inhibitors on angiography-derived coronary microcirculatory resistance and clinical outcomes in patients with coronary heart disease and type 2 diabetes: A cohort study.","authors":"Guangkuo Li, Jianfan Mu, Xuan Liu, Jing He, Fangjie Ji, Weizhan Wang, Yong Liu","doi":"10.1186/s13098-025-01916-0","DOIUrl":"10.1186/s13098-025-01916-0","url":null,"abstract":"<p><strong>Background: </strong>Coronary microvascular dysfunction (CMD) is prevalent in patients with coronary heart disease (CHD) and Type 2 Diabetes (T2DM). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have cardioprotective effects, however, their impact on microcirculatory function is controversial. In this study, we systematically evaluated the effects of SGLT2i on microcirculatory function and clinical outcomes in patients with CHD and T2DM.</p><p><strong>Methods: </strong>This single-center ambispective cohort study retrospectively screened patients with CHD and T2DM who underwent two coronary angiographies from March 2021 to December 2023. Propensity score matching was used to equilibrate baseline factors between two groups: with 106 patients receiving dapagliflozin therapy (experimental group) and 106 patients not receiving dapagliflozin (control group). The retrospective part assessed the effect of SGLT2i on coronary microcirculatory function in patients with CHD and T2DM using the change in Angiography-derived Coronary Microcirculatory Resistance (AMR) from baseline to 12±1 months after treatment as the primary endpoint. The prospective portion of the study followed patients for 15 months to assess clinical outcomes. The study was registered with the China Clinical Trial Registry (ChiCTR2400085512).</p><p><strong>Results: </strong>Baseline characteristics were comparable between groups. The experimental group showed reductions in AMR (from 2.63 to 2.41, P < 0.05). In contrast, the control group exhibited increases in AMR (from 2.58 to 2.78, P < 0.05). Post-treatment intergroup comparisons showed lower AMR in the experimental group (P < 0.05). At 15-month follow-ups, the experimental group had higher 6-minute walk distance (6MWD) and scores across all domains of the Seattle Angina Questionnaire (SAQ) and 36-items Short-form Health Survey (SF-36) (P < 0.05). An exploratory survival analysis revealed statistically significant differences in the survival curves of the two groups (log-rank P = 0.014).</p><p><strong>Conclusion: </strong>This study found that SGLT2i may confer beneficial effects on coronary microcirculatory function, exercise capacity, quality of life, and survival in patients with CHD and T2DM. This provides new evidence for the improvement of coronary microcirculatory function by SGLT2i.</p><p><strong>Trial registration: </strong>China Clinical Trial Registry Identifier ChiCTR2400085512 (Registration date June 11, 2024).</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"380"},"PeriodicalIF":3.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine metabolism characteristics of Alström syndrome in 25 Chinese patients and identification of a new splice site in the ALMS1 gene.","authors":"Huifang Peng, Kailu Li, Bingjie Xue, Yuting Wu, Yu Guo, Xin Cheng, Liujun Fu, Hongwei Jiang","doi":"10.1186/s13098-025-01955-7","DOIUrl":"10.1186/s13098-025-01955-7","url":null,"abstract":"<p><strong>Background: </strong>Alström syndrome is a serious monogenic rare disease with lacking systematic analyses of its endocrine and metabolic characteristics.</p><p><strong>Method: </strong>Clinical data were obtained from Alström syndrome, and group comparison analyses were conducted. Whole exome sequencing was used for molecular diagnosis, and miniGene experiments were performed for the ALMS1 c.9539G > A mutation.</p><p><strong>Result: </strong>Twenty-five patients, 14 males and 11 females, with an average age of diagnosis of 7.3 years, were included. Obesity, insulin resistance, diabetes, thyroid nodules and subclinical hypothyroidism, hyperlipidemia, fatty liver, mild scoliosis and sex hormone abnormalities were common endocrine and metabolic abnormalities, whereas hypokalaemia and pancreatitis occurred only in a single case in this cohort. Among patients with Alström syndrome, the 2-h blood glucose and type III procollagen N-terminal peptide (PIIIPN-P) levels in non-obesity group were significantly greater than that in obesity group. And the TG level of Alström syndrome patients in diabetes group was higher than that in non-diabetes group. Nonsense and frameshift mutations were the main types of ALMS1 gene mutations (90%, 45/50), with c.9151_9152delCT and c.10,822 C > T being the two variants with the highest mutation frequency, accounting for 10% and 8%. c.9539G > A is a variant that affects splicing, resulting in 298 bp deletion of exon 10.</p><p><strong>Conclusion: </strong>Diabetes may exacerbate the development of hyperlipidaemia in Alström syndrome. Obesity management strategies may be adjusted relaxed appropriately for patients with Alström syndrome patients. c.9151_9152delCT and c.10,822 C > T mutations of ALMS1 had the highest variant frequency in this cohort, and c.9539G > A was a new likely pathogenic as splicing variant.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"383"},"PeriodicalIF":3.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C-reactive protein-triglyceride glucose index predicts mortality in cardiovascular-kidney-metabolic syndrome stage 0-3: a prospective cohort study.","authors":"Qianliang Ying, Fan He, Lunzhe Wu, Qucheng Wei, Jian Xu","doi":"10.1186/s13098-025-01947-7","DOIUrl":"10.1186/s13098-025-01947-7","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular-kidney-metabolic (CKM) syndrome is defined by the interplay of metabolic risk factors, chronic kidney disease, and cardiovascular disease. The C-reactive protein-triglyceride glucose index (CTI) is a composite biomarker that reflects both inflammation and insulin resistance, but whether it is associated with mortality in persons with early-stage CKM syndrome is unknown.</p><p><strong>Methods: </strong>We analyzed data from the National Health and Nutrition Examination Survey from 1999 to 2010. We used multivariable Cox proportional-hazards models to assess the association between the CTI score and the risk of all-cause mortality and cardiovascular disease (CVD) mortality, with vital status ascertained through Linkage to the National Death Index through December 31, 2019.</p><p><strong>Results: </strong>Among 10,718 participants, a total of 1783 deaths (491 from CVD) occurred during a mean follow-up of 14.0 years. In fully adjusted models, a higher CTI score was associated with a greater risk of all-cause mortality (HR per unit increase, 1.56; 95% CI, 1.36 to 1.78) and of CVD mortality (HR per unit increase, 2.03; 95% CI, 1.49 to 2.77). The association with all-cause mortality was stronger among participants under the age of 60 than among those over 60 years old (P < 0.001 for interaction).</p><p><strong>Conclusion: </strong>Our study found that in patients with early-stage CKM syndrome, a higher CTI was independently associated with an increased risk of all-cause mortality and CVD mortality. This association was more significant in younger participants.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"382"},"PeriodicalIF":3.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THBS1 regulates the function and insulin sensitivity of HTR8/SVneo cells treated with high glucose through the RhoA/ROCK1 signaling pathway.","authors":"Yuerong Chai, Jie Tang, Aimin Liu, Qin Zhou","doi":"10.1186/s13098-025-01915-1","DOIUrl":"10.1186/s13098-025-01915-1","url":null,"abstract":"<p><strong>Aim: </strong>Gestational diabetes mellitus (GDM) increases the risk of maternal and fetal complications and impairs insulin sensitivity and placental function. This study aimed to explore the effect of thrombospondin-1 (THBS1) on HTR8/SVneo cell function and insulin sensitivity in GDM.</p><p><strong>Methods: </strong>Placental tissues from pregnant women with GDM and normoglycemic pregnant women were collected, and HTR8/SVneo cells were exposed to normal and high glucose conditions. By overexpressing and knocking down THBS1, its effects on cell viability, migration, secretion of inflammatory factors, insulin signaling and glucose uptake were observed. qRT-PCR, Western blot, MTT, scratch test and ELISA were used for detection.</p><p><strong>Results: </strong>Compared with the normal group, the expression of THBS1 in placenta tissue and HTR8/SVneo cells under high glucose conditions in the GDM group was significantly increased. THBS1 overexpression reduced cell viability and migration ability, increased the secretion of inflammatory factors, inhibited insulin signaling, and reduced glucose uptake; on the contrary, THBS1 knockdown significantly improved these indicators. In addition, the activation of the RhoA/ROCK pathway plays an important regulatory role in the effects of THBS1.</p><p><strong>Conclusion: </strong>THBS1 impairs the function and insulin sensitivity of HTR8/SVneo cells by inhibiting insulin signaling and activating the RhoA/ROCK pathway. This indicates that THBS1 may play an important role in the pathogenesis of GDM and become a potential therapeutic target.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"374"},"PeriodicalIF":3.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small left ventricular size as a predictor for incident type 2 diabetes: insights from the UK biobank cardiovascular magnetic resonance substudy.","authors":"Gaifeng Hu, Xiaodong Peng, Liu He, Zixu Zhao, Caihua Sang, Jianzeng Dong, Changsheng Ma","doi":"10.1186/s13098-025-01939-7","DOIUrl":"10.1186/s13098-025-01939-7","url":null,"abstract":"<p><strong>Background: </strong>Left ventricular (LV) concentric hypertrophy is common in diabetes patients, presenting as a relatively small LV size. However, studies have shown that a small LV size can also occur in prediabetic conditions without ventricular hypertrophy. We used data from the UK Biobank Cardiovascular Magnetic Resonance Substudy to assess whether a small LV size independently predicts incident type 2 diabetes.</p><p><strong>Methods and results: </strong>Small LV size was defined using indexed left ventricular end-diastolic volume (iLVEDV) values (< 56 mL/m² for females and < 57 mL/m² for males). The risk of small LV size for incident type 2 diabetes was assessed using adjusted Cox proportional hazards models. The non-linear relationship between iLVEDV and diabetes risk was evaluated using restricted cubic splines. This study included 35,422 participants, with an average age of 64 years, of whom 53.2% were females. Among the 35,422 participants, 947 (2.7%) had small LV size. During a median follow-up of 698 days, 304 cases of incident type 2 diabetes were recorded. Those with small LV size showed a significant association with increased risk of incident type 2 diabetes (adjusted hazard ratio [HR], 2.36; 95% CI, 1.56-3.57). Subgroup analysis consistently supported this relationship across age, sex, hypertension, obesity, and genetic risk for type 2 diabetes. An L-shaped relationship between iLVEDV and diabetes risk was also observed.</p><p><strong>Conclusions: </strong>Small LV size is an independent predictor of incident type 2 diabetes, with a smaller LV size correlating with a higher risk of developing the condition, warranting further investigation.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"375"},"PeriodicalIF":3.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroacupuncture ameliorates cognitive dysfunction in T2DM rats by modulating astrocytic polarization and aberrant energy metabolism in the hippocampus via the Wnt/β-catenin pathway.","authors":"Xiaolu Li, Rui Li, Jiayi Lin, Xiaoli Wu","doi":"10.1186/s13098-025-01941-z","DOIUrl":"10.1186/s13098-025-01941-z","url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment is a frequent but underrecognized complication of type 2 diabetes mellitus (T2DM), closely associated with hippocampal neuroinflammation, glial dysfunction, energy metabolism disruption, and tau hyperphosphorylation. Astrocyte polarization plays a pivotal role in these processes, yet its regulation and impact remain incompletely understood. This study aimed to investigate whether electroacupuncture (EA) alleviates cognitive dysfunction in T2DM rats by modulating astrocytic polarization and hippocampal energy metabolism via the Wnt/β-catenin signaling pathway.</p><p><strong>Methods: </strong>T2DM was induced using a high-fat diet and streptozotocin (STZ) injection. Rats were divided into four groups: Control, Model, EA, and EA + DKK1 (Dickkopf-1, a Wnt/β-catenin inhibitor). EA was applied at Weiwanxiashu (EX-B3), Pishu (BL20), Zusanli (ST36), Yinlingquan (SP9), and Baihui (DU20) for 9 weeks. Behavioral, molecular, and metabolic changes were assessed using the Morris Water Maze, Western blotting, quantitative PCR (qPCR), enzyme-linked immunosorbent assay (ELISA), immunostaining, and targeted metabolomics.</p><p><strong>Results: </strong>EA improved spatial learning and memory, inhibited A1-type astrocyte marker C3, and enhanced A2-type marker S100A10. It also activated Wnt3a, p-GSK3β, nuclear β-catenin, and Ngn2, increased Glut1/Glut3 expression, restored ATP levels, and reduced glycolytic metabolite accumulation. Additionally, EA attenuated tau phosphorylation and neuronal injury. These effects were abolished by DKK1, confirming Wnt/β-catenin involvement.</p><p><strong>Conclusions: </strong>EA ameliorates cognitive deficits in T2DM rats by regulating astrocyte polarization and improving hippocampal energy metabolism through activation of the Wnt/β-catenin signaling pathway. These findings suggest a promising non-pharmacological approach to treating diabetes-related cognitive impairment and highlight the role of astrocytic immunometabolism in diabetic neurodegeneration.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"378"},"PeriodicalIF":3.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between sarcopenia and type 2 diabetes mellitus among adults with prediabetes: evidence from a prospective cohort study.","authors":"Yingxin Liu, Zemin Li, Ruoting Wang, Jingyi Zhang, Hertzel Gerstein, Ai Zhao, Changfa Zhang, Gregory Y H Lip, Harriette G C Van Spall, Guowei Li","doi":"10.1186/s13098-025-01953-9","DOIUrl":"10.1186/s13098-025-01953-9","url":null,"abstract":"<p><strong>Background: </strong>The relationship between sarcopenia and type 2 diabetes mellitus (T2DM) among those with prediabetes is largely inconclusive given the heterogeneous findings of previous studies. We aimed to clarify the association between sarcopenia and prediabetes progression to T2DM in adult participants.</p><p><strong>Methods: </strong>Participants with baseline prediabetes from the UK Biobank cohort were included in this study. Sarcopenia was classified as present or absent based on the criteria from the 2019 European Working Group of Sarcopenia in Older People (EWGSOP2 criteria) including handgrip strength, muscle mass and walking pace. The primary outcome was incident T2DM during follow-up. Multivariable Cox regression model adjusting for sociodemographic factors, lifestyles, comorbidities, and laboratory measures, was used to assess the association between sarcopenia and risk of T2DM.</p><p><strong>Results: </strong>We included 60,325 participants (mean age: 59.6 years, 54.5% females) with baseline prediabetes for analysis, among whom 9,305 (15.4%) had incident T2DM during a mean follow up of 11.4 years. There were 7,139 (11.8%) participants categorized as having sarcopenia. Those with sarcopenia had a higher cumulative incidence of T2DM than those without (19.3% vs. 14.9%, P < 0.001). Sarcopenia was associated with a 22% increased risk of T2DM when compared with no sarcopenia (hazard ratio [HR] = 1.22, 95% confidence interval [CI]: 1.15-1.30) in the fully adjusted model. This association was more evident in participants with a waist to hip ratio < 0.9 (P-value for interaction < 0.05).</p><p><strong>Conclusions: </strong>Sarcopenia was associated with increased risk of T2DM in adults with prediabetes. Sarcopenia appears to be a marker for risk of T2DM in people with prediabetes and interventions targeted at preserving and improving muscle health might be another novel potential approach to effectively decelerating prediabetes progression to T2DM.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"379"},"PeriodicalIF":3.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total bilirubin modifies the relationship between obesity and stroke.","authors":"Junqi Liao, Jingyi Chen, Lianhong Ji, Minghua Wu, Hongquan Liu","doi":"10.1186/s13098-025-01951-x","DOIUrl":"10.1186/s13098-025-01951-x","url":null,"abstract":"","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"373"},"PeriodicalIF":3.9,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mediation of fasting blood glucose between relative muscle strength and hypertension: insights from two cohorts.","authors":"Pengyu Wang, Li Huang, Zhou Zhu, Xinyue Hu, Bingxin Wu, Xiaofang Yang","doi":"10.1186/s13098-025-01949-5","DOIUrl":"10.1186/s13098-025-01949-5","url":null,"abstract":"<p><strong>Background: </strong>Hypertension and type 2 diabetes are major global health burdens and often coexist due to shared metabolic risk factors. Relative muscle strength (RMS), a composite measure of muscle function, shows an inverse association with hypertension. The mechanisms underlying this link remain unclear. Elevated fasting blood glucose (FBG) reflects impaired glucose metabolism and insulin resistance and is associated with both reduced muscle strength and higher blood pressure. This suggests that FBG may partly mediate the RMS-hypertension relationship. Yet, large-scale population studies have rarely tested this mediating pathway, leaving an important knowledge gap.</p><p><strong>Methods: </strong>We analyzed data from two nationally representative cohorts: NHANES (2011-2014;adults aged ≥ 18 Years, mean age 48 years ) and CHARLS (2011-2012; adults aged ≥ 45 Years, mean age 58 years). Hypertension prevalence was nearly 30.0% in NHANES and 42.1% in CHARLS. RMS was calculated as grip strength divided by appendicular skeletal muscle mass (ASM). Hypertension was defined as systolic/diastolic blood pressure ≥ 140/90 mmHg or self-reported diagnosis. Logistic regression examined the RMS-hypertension associations, and causal mediation analysis quantified fasting glucose's mediating role, and restricted cubic spline models were applied to explore potential non-linear relationship.</p><p><strong>Results: </strong>In NHANES (n = 9,652; Hypertension prevalence 30.0%), RMS was inversely associated with hypertension across quartiles (Q2-Q4 vs. Q1: adjusted ORs (95% CIs) of 0.82, 0.78, and 0.72, respectively). Mediation analysis showed fasting glucose partially mediated this association, accounting for 13.1% of this association. In CHARLS (n = 12,946; Hypertension prevalence 42.1%), similar trends were observed (Q2-Q4 vs. Q1: adjusted ORs (95% CIs) 0.91, 0.76, and 0.66), But fasting glucose partially mediated this association, explaining only 2.0% of the association. Restricted cubic spline models revealed significant nonlinearity in CHARLS (P < 0.001) but not in NHANES (P = 0.921).</p><p><strong>Conclusion: </strong>This study is the first to examine the partially mediating role of fasting blood glucose in the RMS-hypertension relationship across diverse populations. RMS was consistently associated with lower hypertension risk, with varying degrees of glucose mediation between cohorts. These findings support integrating RMS assessment into cardiovascular risk screening and highlight muscle strength as a potential target for non-pharmacological prevention. Given the cross-sectional nature of this study, longitudinal research is needed to clarify causal pathways and inform public health strategies.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"372"},"PeriodicalIF":3.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden of chronic liver disease due to NAFLD from 2012 to 2021: A trend, decomposition, and health inequality analysis.","authors":"Yanrui Wu, Zongbiao Tan, Zhou Liu, Yupei Liu, Chuan Liu, Junhai Zhen, Jixiang Zhang, Weiguo Dong","doi":"10.1186/s13098-025-01932-0","DOIUrl":"10.1186/s13098-025-01932-0","url":null,"abstract":"<p><strong>Background: </strong>Non-alcoholic fatty liver disease (NAFLD) is considered to be an important driver of the increasing burden of chronic liver disease (CLD) worldwide. It is necessary to analyze the burden of CLD due to NAFLD (CLD-NAFLD) systematically.</p><p><strong>Methods: </strong>Data related to CLD-NAFLD burden from 2012 to 2021 were obtained from the Global Burden of Disease Study (GBD) 2021. The temporal trend of the incidence and disability-adjusted life years (DALYs) was quantified by average annual percentage change (AAPC). The driving factors of the incidence/DALYs change were explored through decomposition analysis. Slope index and concentration index were employed to investigate cross-country health inequalities.</p><p><strong>Results: </strong>During 2012-2021, the global age-standardized incidence rate (ASIR) of CLD-NAFLD increased from 551.52 to 592.78 (per 100,000 population), while the age-standardized DALY rate (ASDR) decreased from 31.92 to 30.90 (per 100,000 population). North Africa and Middle East had the highest age-standardized prevalence rate (ASPR), East Asia experienced the most rapid increase in ASIR, and Caribbean exhibited the most substantial increase in ASDR. Decomposition analysis showed that the main factors driving the increase in incident cases were population growth and epidemiologic changes, whereas population aging and population growth were the main driving factors for the increase of DALYs. There was cross-country health inequality in the DALYs, which showed a decreasing trend from 2012 to 2021. However, the health inequality in incidence was not significant.</p><p><strong>Conclusions: </strong>The burden of CLD-NAFLD continues to increase. Health policy makers must develop corresponding strategies for the primary health care of metabolic diseases.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"371"},"PeriodicalIF":3.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}